Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Incannex Healthcare Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
IXHL
Nasdaq
2830
www.incannex.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Incannex Healthcare Inc.
Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board
- Feb 4th, 2025 2:15 pm
Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea
- Jan 23rd, 2025 12:30 pm
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025
- Dec 2nd, 2024 9:48 pm
Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates
- Nov 14th, 2024 9:05 pm
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer
- Oct 24th, 2024 11:30 am
Incannex Healthcare Leads The Charge On US Penny Stocks With 2 Other Notable Picks
- Oct 22nd, 2024 4:06 pm
Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)
- Oct 2nd, 2024 8:50 pm
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
- Sep 30th, 2024 8:01 pm
Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors
- Sep 10th, 2024 12:00 pm
Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives
- Sep 9th, 2024 12:00 pm
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed
- Aug 5th, 2024 11:30 am
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X
- Jul 30th, 2024 11:30 am
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
- May 30th, 2024 11:30 am
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
- May 7th, 2024 11:30 am
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)
- May 1st, 2024 6:33 pm
Incannex Healthcare Inc. Quarterly Update, Q1 2024
- Apr 16th, 2024 12:00 pm
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
- Feb 28th, 2024 12:30 pm
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation
- Feb 16th, 2024 12:30 pm
Scroll